1 / 31

Presented By Franco Cavalli at 2014 ASCO Annual Meeting

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients ineligible for bone marrow transplantation . Presented By Franco Cavalli at 2014 ASCO Annual Meeting.

zilya
Télécharger la présentation

Presented By Franco Cavalli at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients ineligible for bone marrow transplantation Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  2. Background Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  3. Study Aim Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  4. LYM-3002 Study Design Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  5. Endpoints Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  6. Statistical Assumptions Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  7. Demographics and Baseline Characteristics Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  8. Treatment Exposure Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  9. Superior PFS by IRC with VR-CAP vs R-CHOP: 59% improvement Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  10. Depth and duration of response by IRC improved with VR-CAP Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  11. Secondary outcomes:<br />TTP, TTNT, TFI, OS Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  12. Secondary Outcome: OS Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  13. Overall Safety Profile Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  14. Grade ≥3 AEs and Serious AEs Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  15. Hematologic AEs and Clinical Significance Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  16. Peripheral Neuropathy Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  17. Conclusions – Efficacy Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  18. Conclusions – Safety Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  19. Final Conclusion Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  20. Acknowledgments Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  21. Slide 21 Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  22. PFS by Investigator Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  23. PFS by IRC – Subgroup Analyses Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  24. PFS by Stratification Factors Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  25. PFS by Geographic Region Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  26. Efficacy in Patients Without Medical Reasons for Transplant Ineligibility Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  27. Baseline MIPIb distribution and PFS by MIPIb Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  28. Efficacy by Ki-67 expression (N=327) Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  29. Responses by investigator Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  30. All-Grade AEs (≥20%, either arm) Presented By Franco Cavalli at 2014 ASCO Annual Meeting

  31. Deaths Presented By Franco Cavalli at 2014 ASCO Annual Meeting

More Related